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Abstract: Central to the progression of cerebral toxoplasmosis is the interaction of Toxoplasma
gondii with the blood-brain barrier (BBB) endothelial cells. In the present work, we tested the
hypothesis that inhibition of Wnt pathway signalling by the monovalent ionophore monensin
reduces the growth of T. gondii infecting human brain microvascular endothelial cells (hBMECs) or
microglial cells. The anti-parasitic effect of monensin (a Wnt signalling inhibitor) on the in vitro
growth of T. gondii tachyzoites was investigated using two methods (Sulforhodamine B staining
and microscopic parasite counting). The monensin inhibited T. gondii growth (50% inhibitory
concentration [IC50] = 0.61 µM) with a selective index = 8.48 when tested against hBMECs (50%
cytotoxic concentration [CC50] = 5.17 µM). However, IC50 of monensin was 4.13 µM with a SI = 13.82
when tested against microglia cells (CC50 = 57.08 µM), suggesting less sensitivity of microglia cells
to monensin treatment. The effect of T. gondii on the integrity of the BBB was assessed by the
transendothelial electrical resistance (TEER) assay using an in vitro human BBB model. The results
showed that T. gondii infection significantly decreased hBMECs’ TEER resistance, which was rescued
when cells were treated with 0.1 µM monensin, probably due to the anti-parasitic activity of monensin.
We also investigated the host-targeted effects of 0.1µM monensin on global gene expression in hBMECs
with or withoutT. gondii infection. Treatment of hBMECs with monensin did not significantly influence
the expression of genes involved in the Wnt signalling pathway, suggesting that although inhibition
of the Wnt signalling pathway did not play a significant role in T. gondii infection of hBMECs,
monensin was still effective in limiting the growth of T. gondii. On the contrary, monensin treatment
downregulated pathways related to steroids, cholesterol and protein biosynthesis and their transport
between endoplasmic reticulum and Golgi apparatus, and deregulated pathways related to cell
cycle and DNA synthesis and repair mechanisms. These results provide new insight into the
host-modulatory effect of monensin during T. gondii infection, which merits further investigation.
Keywords: Toxoplasma gondii; monensin; TEER; gene expression; Wnt signaling
1. Introduction
Toxoplasma gondii is an obligate intracellular apicomplexan protozoan parasite that is widely
distributed throughout the world. The disease associated with T. gondii infection, toxoplasmosis,
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can lead to severe central nervous system (CNS) pathologies [1]. Although T. gondii infection is usually
asymptomatic in healthy individuals, infection can be fatal in immunocompromised patients and in
congenitally infected fetuses [2,3]. Given the pathological damage and neuroinflammation that can be
caused by T. gondii infection of the brain [4,5], many epidemiological studies have shown an association
between T. gondii infection and a number of neuropsychiatric conditions, such as schizophrenia and
bipolar disorder [4–6]. Besides the lack of a vaccine, current treatment options for toxoplasmosis are
limited and responses to commonly used medicines are often unsatisfactory [7]. There is a clear need
for new and more potent anti-T. gondii therapeutics to reduce the clinical impact of toxoplasmosis.
Ideal therapeutic agents should prevent parasite growth, without perturbing the proliferation or
homeostasis of host cells. However, in general, although available therapeutic agents display potent
anti-T. gondii properties, many are cytotoxic to mammalian cells [8].
The blood-brain barrier (BBB) is the initial site of interaction between neuro-pathogens such
as T. gondii and the mammalian brain [9]. Breaching this protective biophysical barrier is a key
mechanism by which T. gondii tachyzoites invade and damage the CNS [9]. During T. gondii infection,
different signalling pathways control the expression of a wide range of genes that orchestrate molecular
and cellular events to eliminate the invading parasite and regulate the associated inflammation [10].
One of these pathways is the Wnt pathway, which is considered an important regulatory axis in the
immune system, where genes involved in this pathway were upregulated in T. gondii-infected mice [10].
Moreover, other intracellular pathogens have been shown to manipulate this pathway to facilitate
their entry into the cell and establish infection, such as Chlamydia trachomatis [11] and the influenza
virus [12].
Small molecule inhibitors of the Wnt pathway are becoming more prominent in the pharmaceutical
industry [13], and are increasingly being used to target cancer cells and intracellular pathogens [14].
Natural polyether ionophores, such as monensin, have been substances of great interest, because of their
antimicrobial activities [15]. Monensin has been extensively used in veterinary applications as a growth
promoter [16] and to treat coccidiosis and cryptosporidiosis [15,17]. In addition, monensin was proposed
as an anticancer agent [18,19]. Monensin, secreted by the bacteria Streptomyces cinnamonensis, has been
shown to modulate Wnt signalling by antagonizing β-catenin and the lipoprotein receptor-related
protein LRP [18]. Investigation into how manipulation of the Wnt pathway by monensin can influence
the growth of T. gondii could be beneficial in the development of new anti-T. gondii therapeutics.
In this study, we investigated whether inhibition of the Wnt signalling pathway by monensin
can reduce the growth of T. gondii infecting human brain microvascular endothelial cells (hBMECs) or
microglial cells, and whether suppression of the growth of T. gondii within hBMECs using monensin can
restore the impairment of the BBB integrity. We also performed systems-level transcriptional analysis
of hBMECs infected by T. gondii in the presence or absence of monensin to obtain a comprehensive
insight into how monensin treatment alters gene expression of hBMECs during T. gondii infection.
2. Materials and Methods
2.1. Chemicals
Monensin was purchased as a sodium salt powder from Alfa Aesar (Ward Hill, MA, USA) and
1.73 mg was dissolved in 250 µL of absolute methanol. The 10 mM of stock solution was diluted
with complete culture medium to prepare five working concentrations 0.01 µM, 0.1 µM, 1 µM, 10 µM
and 100 µM, which were stored at 4 ◦C until use. Sulforhodamine B (SRB) was purchased from
Sigma-Aldrich (SIGMA-ALDRICH®/Merck KGaA, Darmstadt, Germany) and a solution of 0.4% (w/v)
SRB dissolved in 1% acetic acid (Fisher Scientific, Leicestershire, UK) was prepared and stored protected
from light at 4 ◦C.
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2.2. Cell Lines
Primary human brain microvascular endothelial cells (hBMECs) kindly provided by Naveed Khan
(American University of Sharjah, Sharjah, UAE) were maintained in modified Gibco® Roswell Park
Memorial Institute (RPMI) 1640 media (Thermo Fisher Scientific, Waltham, MA, USA) containing 20%
Gibco® Heat Inactivated Fetal Bovine Serum (HI-FBS), 1% Gibco® non-essential amino-acids (100×),
1% Gibco® sodium pyruvate (100 mM), 1% Gibco® MEM vitamins (100×), 1% L-glutamine (200 mM),
and 1% Gibco® antibiotic-antimycotic solution 100× (10,000 units/mL of penicillin, 10,000 µg/mL of
streptomycin, and 25 µg/mL of Amphotericin B). Human microglial cells (ATCC CRL-3304) originally
obtained from the American Type Culture Collection were grown in modified Gibco® Dulbecco’s
Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) containing 5% Gibco®
HI-FBS and 1% Gibco® antibiotic-antimycotic solution 100X. Both cell lines were passaged twice a
week and grown in T75 (75 cm2) NUNC™ tissue culture flasks (Fisher Scientific, Leicestershire, UK)
for two weeks before being used in the experiments. All cultures were maintained in a cell culture
incubator at 37 ◦C with 5% atmospheric CO2.
2.3. Parasite Strain and Culture Conditions
Tachyzoites of the T. gondii RH strain were cultured in NUNC™ T75 tissue culture flasks containing
hBMECs using the same cell culture conditions described above. The tachyzoites were harvested from
their feeder cell cultures when 70–80% of the hBMECs were lysed in about three days. Then, they were
separated from host cell debris via centrifugation at 500 g for 5 min. Based on the cell line used in
the subsequent experiments, the number of tachyzoites was adjusted with the respective medium
(RPMI for hBMECs or DMEM for microglial cells) to achieve a multiplicity of infection (MOI) of 5
(5 tachyzoites: 1 cell) for each cell line.
2.4. Efficacy of Monensin on the In Vitro Growth of T. gondii
We used parasite counting assay in 24-well plates and the sulforhodamine B (SRB) assay in 96-well
plates to investigate the effects of inhibition of the Wnt signalling pathway using monensin on the
intracellular growth of T. gondii.
2.4.1. Parasite Counting Assay
Microglial and hBMEC cultures were seeded on Nunclon™ Delta Surface 24-well culture plates
(Thermo Fisher Scientific, Waltham, MA, USA) at seeding densities of 5 × 104 cells and 105 cells per
well, respectively. Cultures of both cell types were infected with T. gondii tachyzoites at a MOI of 5.
Approximately 3 h post-infection, the culture medium in each well was discarded and replaced with
1 mL of fresh medium supplemented with one of the five working concentrations of monensin (0.01 µM,
0.1 µM, 1 µM, 10 µM and 100 µM). Growth of cell cultures was monitored daily by microscopic
observation using a Zeiss Axiovert 25 inverted microscope (Leica Microsystems, Milton Keynes, UK)
with a 10X objective lens. When the parasites had completed a few cycles of development and began to
exit the cells in large numbers at ~3 days after infection of the untreated cells, the absolute number of
tachyzoites in each well of treated and untreated cultures was counted. To achieve this, the remaining
medium in the wells was topped up with phosphate buffered saline (PBS) with pipetting to produce a
homogenous parasite suspension. A small amount (50 µL) of the suspension from each well was used
to count tachyzoites using a standard hemocytometer counting slide.
2.4.2. Colorimetric SRB Assay
The SRB assay involves the measurement of cellular protein content using a plate reader to
quantify the absorbance after cells have been fixed and stained with SRB dye. The SRB absorbance
values represent the spectrophotometric quantification of protein concentration of the cells, which is
directly proportional to the number of cells (i.e. increased absorbance correlates with increased protein
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content, which reflects an increase in the cells’ number). Hence, SRB absorbance values can be used as
an indicator of host cell proliferation rates in T. gondii-infected versus mock-infected (control) cultures
to determine the level of T. gondii growth indirectly. Based on this rationale, we can expect infected cells
to produce less absorbance due to the disruption of cell proliferation caused by the damaging effects of
the parasite growth on the host cell viability. Here, a microplate-based SRB staining assay was used as
a simple, cost-effective, convenient approach to determine the inhibitory effect of monensin on T. gondii
growth in vitro. Briefly, cells were cultured in Corning® Costar® 96-well plates (Sigma-Aldrich/Merck
KGaA, Darmstadt, Germany). Each well was seeded with 5 × 103 microglial cells or 104 hBMECs in
100 µL of the respective medium and then grown to confluency (~1 day). Tachyzoites used to infect
each well at a MOI of 5 were able to invade the host cells within 3 h. Then, the medium was discarded
to remove any extracellular tachyzoites and 100 µL of media containing one of the five concentrations
of monensin (0.01 µM, 0.1 µM, 1 µM, 10 µM, and 100 µM) was added to each well. Wells that received
medium without monensin (untreated) served as controls. After five days of incubation, the SRB assay
was performed according to Vichai and Kirtikara [20]. Ice-cold 100 µM of 10% trichloroacetic acid
(TCA) solution (Fisher Scientific, Leicestershire, UK) was added to each well. The plates were kept at
4 ◦C for 1 h. Afterwards, the solution was discarded from the wells followed by thorough washing with
distilled water. Next, 25 µL of SRB dye was added to each well and incubated for 15 min at ambient
temperature. The plates were wrapped with foil to protect the dye from the light. Then, the wells were
washed with 1% acetic acid to remove any unattached stain, followed by addition of 100 µL of 10 mM
Tris base solution (Sigma-Aldrich/Merck KGaA, Darmstadt, Germany) to each well. Finally, the plates
were gently agitated on a plate shaker at 35 rotations/min for 5 min to ensure a homogeneous solution.
The absorbance was measured at 492 nm using a plate reader (LT-4000 Microplate Reader, LabTech
International Ltd., Heathfield, UK).
2.5. Effect of Monensin on BBB Integrity
The hBMECs are fundamental constituents of the BBB and play important roles in the maintenance
of barrier integrity. To determine if and to what extent integrity of hBMECs is affected by exposure to
0.1 µM monensin in the presence or absence of T. gondii infection, transendothelial electrical resistance
(TEER) was measured. Briefly, 0.5 µM PET-inserts (24-well Millicell® Cell Culture Inserts, Millipore,
Watford, UK) were fitted to wells of the 24-well culture plates. Then, 104 cells in 100 µL of RPMI
medium were added to each insert and 100 µL of the culture medium was added to the bottom of
the well. The plate was incubated for 1 h; then the medium was discarded and replaced with 1.3 mL
fresh media in the bottom of each well. Also, 300 µL fresh media was added onto the cell monolayer
inside the inserts. Three days after seeding the cells, the media in the inserts and wells were discarded
and replaced with fresh media. Six days after seeding, one of the plates was infected with T. gondii by
removing old media and adding tachyzoites at a MOI of 5, in fresh medium, to the inserts. The plate
was incubated for 1 h before addition of monensin-supplemented RPMI or fresh RPMI (control) to
hBMEC monolayer growing on the apical (top) side of insert. TEER was measured in each insert daily
for 4 successive days. TEER was measured using an Evom voltohmmeter with the Endohm 12 and
STX2 electrodes (World Precision Instruments, Inc., Sarasota, FL, USA). The electrodes were placed
into the insert membrane and bottom of each well. TEER values were measured three times from each
well, while changing the position of the electrodes slightly each time in order to obtain the overall
average of the insert resistance. A background resistance was established by placing the electrodes
into inserts with a blank medium only, without cells. This value was used to calculate the TEER value
of each well using the equation (TEER (cells) = (TEER(total) − TEER(blank)) culture area). The culture
area of the insert was 0.33 cm2. The TEER value was expected to increase with increased resistance of
the hBMEC monolayer.
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2.6. Microarray Analysis
The aim of this experiment was to identify the effect of 0.1 µM monensin on the overall expression
of host cell genes, and in particular on the expression of genes involved in the Wnt signalling pathway.
We used cDNA microarrays to detect changes in mRNA expression in four experimental groups.
These included: uninfected, un-treated hBMECs (Control); hBMECs treated with 0.1 µM monensin for
24 h (Monensin_only); T. gondii infected-hBMECs for 24 h (TG_only); and T. gondii-infected hBMECs
treated with 0.1µM monensin after 3 h of infection and incubated for further 24 h (TG_Monensin).
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Manchester, UK) and eluted with
nuclease-free water. The extracted RNA was stored at −80 ◦C for one week prior to microarray
analysis. All subsequent sample handling, labelling, and GeneChip (GeneChip Human Gene 1.0 ST
arrays, Affymetrix, Santa Clara, CA, USA) processing were performed at the transcriptomics service at
Nottingham Arabidopsis Stock Centre (NASC). The RNA concentration and quality were assessed
using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) and the RNA
6000 Nano kit (Caliper Life Sciences, Mountain View, CA, USA), respectively, prior to the microarray
analysis. Only RNA samples with a minimum RNA concentration of 100 ng/µL and RNA integrity
number (RIN) value > 8 were used for microarray analysis.
Single-stranded complimentary DNA was prepared from 200 ng of total RNA as per the Ambion®
WT Expression Kit’s instructions (Thermo Fisher Scientific, Paisley, UK) for Affymetrix GeneChip
Whole Transcript WT Expression Arrays (Affymetrix, Wycombe, UK). Total RNA was first converted
to cDNA, followed by transcription to make cDNA. Single-stranded cDNA was synthesized, end
labelled, and hybridized for 16 h at 45 ◦C to Human Gene 1.0 ST arrays (Affymetrix, Wycombe, UK).
All liquid handling steps were performed by a GeneChip Fluidics Station 450 and GeneChips were
scanned with the GeneChip Scanner 3000 7G (Affymetrix, Wycombe, UK) using Command Console
v3.2.4. The microarray data have been deposited in the ArrayExpress database at EMBL-EBI (Available
online: www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-8817.
The R package software (R Studio Inc., Boston, MA, USA) was used to process the data. Briefly,
a data file, called ‘pdatamon’ was created to link each microarray data file with ‘.ga.cel’ ending
to one of the four experimental groups (i.e. Control, Monensin_only, TG_only, TG_Monensin).
The libraries of modules (oligo, gplots, RColorBrewer, pvclust, colourspace, limma, gene filter,
hugene21sttranscriptcluster.db) needed for quality control, differential gene expression and transcript
cluster ID annotation were downloaded and uploaded into the workspace. Next, Affymetrix microarray
data files were uploaded together with ‘pdatamon’ file. Quality control analysis and normalization
were performed using the robust multi-array average (RMA). RMA normalization is sensitive for low
expression values, and provides consistent fold-change estimates, and excellent background adjustment
compared to MAS 5.0 and dChip normalization methods [21,22]. Only genes exhibiting a fold-change
FC ≤ −1 (downregulated) or FC≥ 1 (upregulated) relative to control and an adjusted p-value < 0.05
were considered as differentially expressed genes (DEGs). The ranked list of DEGs were included
in subsequent analyses. Comparison was made between control (untreated + uninfected) hBMECs
and each of the other three groups, including hBMECs treated with monensin (Monensin_only),
T. gondii-infected hBMECs treated with monensin (TG_Monensin), and hBMECs infected with T. gondii
only (TG_only).
2.7. Gene Ontology (GO) Analysis
Functional annotations of the valid DEGs and statistical overrepresentation of the GO terms in
the categories of biological processes, molecular functions, and cell components [23], were retrieved
in accordance with instructions [24,25], using the PANTHER online database (Available online:
www.pantherdb.org). The PANTHER library of annotated genes (Homo sapiens) was used as reference
list for calculating statistical overrepresentation with a false discovery rate (FDR) < 0.05 considered
significantly enriched.
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2.8. Pathway Enrichment Analysis
The DEGs genes were functionally annotated and positioned within the respective biological
pathways using the Reactome pathway database (Available online: https://reactome.org) and the
Reactome Analysis Tool version v65 (Available online: https://reactome.org/PathwayBrowser/#TOOL=
AT). Significance was estimated using hypergeometric testing and FDR was controlled for using the
Benjamini–Hochberg procedure. Pathways with FDR < 0.01 were considered significantly enriched.
2.9. Statistical Analysis
Statistical analysis was performed using a Student’s t-test (two independent groups), one-way
ANOVA (multiple groups, one independent factor) or two-way ANOVA (multiple groups, two
independent factors) followed by a Bonferroni–Holm post hoc test using GraphPad Prism 7 software
for Windows (GraphPad Software, San Diego, CA, USA). The mean of at least three independent
experiments is presented, with error bars in the graphs showing the standard error of the mean (SEM).
Differences were considered statistically significant at a p value of < 0.05. The level of significance was
reported as: * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. The drug concentration that caused
50% inhibition of host cell growth was expressed as 50% cytotoxic concentration (CC50). The CC50 of
monensin on microglia and hBMECs were calculated by plotting dose-response curves followed by
performing simple linear regression analysis using Graph Pad Prism 7 software. The calculation of the
half-maximal inhibitory concentration (IC50), which is the concentration of monensin that caused a 50%
decrease of T. gondii growth compared to the control in both cell lines, were calculated using Graph
Pad Prism 7’s nonlinear regression (curve fit) built-in analysis tool of dose-response inhibition (three
parameters). The selectivity index (SI), which represents the ratio of the CC50 for host cells to the IC50
for T. gondii, was calculated by comparing the cytotoxicity of monensin for host cells to that of T. gondii.
3. Results
3.1. Antiparasitic Effect of Monensin
The tachyzoite counts were carried out to measure the effect of monensin on the in vitro growth
of T. gondii. The results showed a significant decrease (p < 0.01; ANOVA) in the number of counted
tachyzoites in a dose-dependent manner, and >90% and 70% inhibition of T. gondii was achieved
at 1 µM monensin concentration in hBMECs and microglial cells, respectively. The inhibitory effect
of monensin on parasite growth was relatively greater in infected hBMEC cultures from 0.1 µM to
100 µM concentration. However, 0.1 µM was considered the minimal concentration to cause significant
antiparasitic effects because no significant reduction in the tachyzoite counts was caused by higher
concentrations and the reduction was not significantly different between hBMECs and microglia cells
(Figure 1).
It was important to test the effects of monensin on hBMECs and microglia in the absence of
T. gondii infection. The SRB-based results showed lack of significant difference in cell density levels
between infected and non-infected cultures of both hBMECs and microglia at low levels of monensin,
suggesting that the number of treated + infected cells did not significantly decrease more than the
control cells, probably due to inhibition of T. gondii infection by monensin (Figure 2). We performed
t-tests to draw comparisons on the effect of each concentration of monensin between infected and
non-infected cultures of each cell line. None of the data showed any significant differences except the
10 µM treated-hBMEC cultures and 100 µM treated-microglia cultures. The density of both infected
and non-infected hBMEC cultures showed significant decrease (p < 0.05) within the entire range of the
tested concentrations (0.01 µM to 100 µM). However, when the same SRB assay was performed on
microglia culture (infected and non-infected), there was no significance reduction in cell density.
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Figure 1. Toxoplasma gondii tachyzoite growth inhibition in microglia and human brain microvascular
endothelial cell (hBMEC) cultures was dependent on monensin concentration. The parasite growth was
inhibited (compared to parasite growth in untreated cells) as the concentration of monensin increased,
but at 0.1 µM the inhibitory effect reached a plateau. Data represent mean values (± SEM) of triplicate
from two independent experiments for each cell line.
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Figure 2. Microglia and hBMEC cultures showed different sensitivity to monensin. Relative growth
of each cell line was assessed by the sulforhodamine B (SRB) assay. The relative absorbance values
of infected and treated cells were compared to non-infected and treated (control) cells. A significant
decrease in cell number was observed in infected and uninfected hBMECs with increasing monensin
concentration compared to microglia cultures. Data represent mean values (± SEM) of five replicates
from three independent experiments for each cell line. Multiple Student t-tests; *, p < 0.05.
It is worthwhile to highlight that the SRB approach does not distinguish between anti-T. gondii
effect and hos cell toxicity characteristics, since death of host cells carrying the parasite could be
related to cell toxicity caused by monensin as well as, or in lieu of, any anti-T. gondii effect. Therefore,
it is possible that the anti-T. gondii effect of monensin in infected hBMECs may be confounded by the
toxic effect of monensin on these cells. The 50% inhibitory concentration (IC50) for T. gondii tachyzoites
(0.61 µM) and half-maximal cytotoxic concentrations (CC50) for hBMECs was 5.17 µM. The selective
index (SI) was calculated as the CC50/IC50 of monensin and was found to be 8.48. However, the observed
effects of monensin seem to be specific to host cell sensitivity to monensin and independent of the
direct anti-T. gondii effect, since treatment with monensin did not induce the same cytotoxic effect
in microglia cultures, where IC50 of monensin was 4.13 µM with a SI = 13.82 when tested against
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microglia (CC50 = 57.08 µM). These results show that although monensin reduced the growth rates of
T. gondii tachyzoites in both hBMECs and microglia cells, the SI was higher in microglia cells compared
to hBMECs, suggesting less sensitivity of microglia cells to monensin treatment.
3.2. Assessment of hBMEC Monolayer Integrity
We investigated how hBMEC integrity was affected by T. gondii infection and/or modulated by
Wnt inhibition via exposure to 0.1 µM monensin. The effect of monensin on the TEER of infected and
uninfected hBMECs was monitored over 4 days. At one day post infection, there was no significant
(p ≥ 0.05; t-tests) difference between T. gondii-infected cells treated with 0.1 µM monensin compared to
infected + untreated, probably because it takes about a day for infection to establish. However, from day
2 after infection there was a significant decrease in hBMECs’ TEER between 0.1 µM monensin-treated
and untreated infected cells. Interestingly, infected and treated cells did not show any significant
difference throughout the entire experiment, suggesting that cell integrity was maintained by monensin
treatment, possibly via inhibiting the damage caused by the parasite growth (Figure 3). On the contrary,
the infected and untreated cells showed a significant reduction in TEER readings compared to the
infected and treated cells (p < 0.05), suggesting that T. gondii infection significantly compromised host
cell integrity. There was a 38.2% decrease in the resistance of infected + untreated cells compared to
infected + treated cells relative to the control cells. Interestingly, hBMECs’ resistance did not change
significantly from day to day and cell integrity was generally stable over the time period for control,
infected + treated, and 0.1 µM monensin only groups. These findings are in line with the results
of the anti-T. gondii effect of monensin (Figures 1 and 2), suggesting that monensin had offset the
cellular damage through inhibition of the parasite growth within the hBMECs and, hence, enhanced
the recovery of cell integrity, leading to better endothelial resistance than infected + untreated cells.
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3.3. Microarray Quality Control Analysis
The transcriptome analysis included four experimental groups: (i) uninfected and untreated
hBMECs (Control—C2YA; C2YB; C2YC); (ii) uninfected hBMECs treated for 24 h with 0.1 µM
monensin (Monensin_only—0.1µM_A; 0.1µM_B; 0.1µM_C); (iii) hBMECs infected with T. gondii only
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(TG_only—Inf 24 A; Inf 24 B; Inf 24 C); and (iv) T. gondii-infected hBMECs treated for 24 h with
0.1 µM monensin after 3 h of infection (TG_Monensin—TG + 0.1µMA; TG + 0.1µMB; TG + 0.1µMC).
The 0.1 µM concentration was selected for the array experiment because preliminary data revealed that
this concentration was just sufficient to trigger the cell’s transcriptional response (unpublished data)
and also to avoid the growth inhibition of hBMECs that would have occurred at higher concentrations.
The overall distribution between microarray files of the examined samples indicated that normalization
was required before the samples are analyzed. As shown in the pre-normalization box plot (Figure S1A),
the distributions of all sample median expression values were not uniform before normalization,
which might lead to under- or over-estimated expression values if samples were compared. Following
normalization, the median expression values of all samples became more uniform (Figure S1B).
3.4. Correlation Between Samples
Hierarchical clustering was performed to show the level of correlation between the transcriptional
profiles of all 12 samples (based on the top 50 most significantly expressed genes) and identified four
distinct subgroups (Figure 4A). Based on the dendrogram, four experimental groups, representing 12
expression profiles, were segregated into four clusters. These four clusters corresponded to four groups
(TG_only, TG_Monensin, Monensin_only, Control_only) where three replicates within each group had
similar expression patterns. As shown in the dendrogram, the expression profile of TG_only group was
different from the expression profiles of the other three groups, namely Control_only, Monensin_only
and TG_Monensin. Principal component analysis (PCA) also showed similar clustering of samples into
four distinct groups, where samples within each group were clustered together. However, despite the
high degree of concordance between the replicates per group, the TG + 0.1µM_C sample did not fully
cluster with the other two replicates of the TG_Monensin group, which might be attributed to sample
to sample variation within the group (Figure 4B). Moreover, TG_Monensin group and Monensin_only
group samples clustered together and their gene expression profiles were more similar than those of
the TG_only group samples. The overall expression values between the three experimental groups
compared to the Control_only group is displayed as a Venn diagram (Figure 5). This diagram shows
the shared and unique DEGs between the three comparison groups. Table S1 lists 19 DEGs that are
shared by all three comparison groups. The TG_only had more total DEGs compared to the other two
groups (Monensin_only and TG_Monensin).
3.5. Expression Patterns of Altered Genes
Here, the transcriptional response of hBMECs treated with monensin in the presence or absence
of T. gondii infection was investigated in order to obtain more insight into the mechanism of action of
monensin against T. gondii.
3.5.1. Control vs. Monensin_only
Treatment of hBMECs with 0.1 µM monensin induced more upregulation of genes than
downregulation (Figure 6A). A total of 480 DEGs were identified; 368 were upregulated and 112 were
downregulated. Among the 480 DEGs, 244 were not annotated (NA) and 236 were annotated. Out of
the annotated genes, 171 were upregulated and 65 were downregulated. The top 30 most significant
DEGs induced by monensin treatment and their name, gene symbol, gene description, and log2 FC
values are listed in Table S2. The most significantly annotated gene was ‘DNA damage inducible
transcript 3′ (DDIT3) with a log2 FC of 2.984. In addition, the top 30 upregulated and downregulated
genes are listed in Tables S3 and S4, respectively. Among these, the most highly upregulated gene
was also DDIT3, whereas the most highly downregulated gene with annotation was ‘small nucleolar
RNA, C/D box 116-24′ (SNORD116-24) with a log2 FC of −2.543. The heatmap shows a correlation
between samples based on the top 30 most significant DEGs after 24 h treatment with 0.1 µM monensin
(Figure 6D).







Correlation heatmap of samples
B
Principal Component Analysis
Figure 4. (A) A heatmap showing the correlation between all 12 microarray transcriptome expression
profiles based on the top 50 most significantly expressed genes. Shades of light green and dark blue
represent low and high correlation, respectively. Based on the dendrogram, four groups of the 12
sample expression profiles were clustered into four distinct clusters, where three samples within each
group had similar expression profiles. (B) Principal component analysis (PCA) plot also shows that
samples within each group were similar to each other, with the only exception being the dataset of
TG_Monensin group samples.
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Figure 5. Three-way Venn diagram comparing expression profiles of Control vs. TG_only, Control
vs. Monensin_only and Control vs. TG_Monensin. Numbers in the overlapped areas (i.e. at the
intersection of the circles) represent DEGs shared between groups. The shaded area in the middle
represents 19 DEGs shared between the three groups (Table S1).
3.5.2. Control vs. TG_Monensin
The overall expression profile of hBMECs infected with T. gondii and treated with 0.1 µM
monensin (TG_Monensin) for 24 h is shown (Figure 6B). Overall, there were more upregulated genes
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than downregulated genes. A total of 424 DEGs passed the selection criteria, of these 134 were
upregulated and 290 were downregulated. Among the 424 DEGs, 114 were without annotation (NA)
while 310 were annotated. Focusing on the annotated genes, 201 of them were upregulated, but 109
were downregulated. The top 30 most significant DEGs in hBMECs infected with T. gondii and treated
with 0.1 µM monensin (TG_Monensin) are listed in Table S5. Among these, the most highly significant
upregulated genes with annotation were DDIT3 with a log2 FC of 2.446 and ‘homocysteine inducible
ER protein with ubiquitin-like domain 1′ (HERPUD1) with a log2 FC of 2.199. The top 30 upregulated
and downregulated genes are listed in Tables S6 and S7, respectively. The most upregulated gene was
‘uncharacterized LOC105369371′ (LOC105369371) with a log2 FC of 5.135 and the most downregulated
gene was ‘endothelin 1′ (EDN1) with a log2 FC of −1.960. Figure 6E depicts the heatmap showing a
correlation between samples based on to the top 30 most significant DEGs in hBMECs infected with







Figure 6. (A–C) Volcano plots showing the expression profile of hBMECs treated with 0.1 µM monensin
(Monensin_only), hBMECs treated with 0.1 µM monensin + infected by T. gondii (TG_Monensin),
and hBMECs infected by T. gondii (TG_only), compared to control hBMECs. The red horizontal line
represents a cut-off value of p < 0.05 and the vertical dash red lines represent the log2 FC cut-off
value of ≤ −1 (downregulated) or ≥ 1 (upregulated). Generally, more upregulated genes passed both
cut-off values than down-regulated genes. (D–F) Correlation heatmaps of the top 30 most significant
DEGs following treatment with monensin, following treatment + infection, and following infection,
compared to control. The rows represent DEGs and the columns represent the 12 examined samples.
The dendrogram shows a high intra-sample correlation between each group for all groups. Genes
labelled as NA (not available) denote unpublished genes or uncharacterized non-coding RNA genes
without annotation.
3.5.3. Control vs. TG_only
The overall expression profile of hBMECs infected with T. gondii (TG_only) for 24 h showed that
more genes were upregulated than downregulated (Figure 6C). The total number of genes that passed
selection criteria was 902 genes, with 353 of them were upregulated while 549 were downregulated.
Among the 902 DEGs, 454 were without annotation (NA), while the remaining 448 were annotated.
For the annotated genes, 345 of them were upregulated, whereas 103 were downregulated. The top 30
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most significant DEGs from TG_only samples are listed in Table S8. Among these, the most highly
significant upregulated gene with annotation was ‘epithelial cell adhesion molecule’ (EPCAM) with a
log2 FC of 2.249. The top 30 upregulated and downregulated genes are listed in Tables S9 and S10,
respectively. Among these, the most highly upregulated gene with annotation was ‘metallothionein
1M’ (MT1M) with a log2 FC of 4.414 and the most highly downregulated gene with annotation
was ‘microRNA 29a’ (MIR29A) with a log2 FC of −3.201. Figure 6F depicts the heatmap showing a
correlation between samples based on the top 30 most significant DEGs from 24 h T. gondii infection.
3.6. Gene Ontology (GO) and Pathway Analysis
Here, the transcriptional changes in hBMECs in response to treatment with 0.1 µM monensin
(Monensin_only), T. gondii infection (TG_only), and T. gondii infection plus treatment with 0.1 µM
monensin (TG_Monensin) were investigated. For this analysis, only annotated genes were considered.
Out of 112 downregulated genes, only 65 (58.03%) were annotated, whereas 171 out of 368 (46.47%)
upregulated genes were annotated in the Monensin_only group. Regarding Control vs. TG_Monensin,
109 out of 134 (81.34%) downregulated genes were annotated, and 201 out of 290 (69.31%) up-regulated
genes were annotated. For Control vs. TG_only, 103 out of 353 (29.18%) downregulated genes were
annotated, but 345 out of 549 (62.84%) upregulated genes were annotated.
3.6.1. Control vs. Monensin_only
Of the 65 annotated downregulated genes, 54 were recognized by PANTHER database and
the GO terms belonging to the categories of biological process (BP), molecular function (MF),
cellular compartment (CC) are presented in Figure 7A–C, respectively. Overall, 54 genes matched 11 GO
terms of BP, including cellular process, metabolic process, cellular component organization or biogenesis,
biological regulation, response to stimulus, developmental process, multicellular organismal process,
localization, reproduction, rhythmic process, and locomotion. Using PANTHER Overrepresentation
Test with the default setting (Fisher’s Exact with FDR multiple test correction) for PANTHER GO-Slim
Biological Process, 11 out of 92 BPs were remarkably enriched (FDR < 0.05). These included
DNA metabolic process, cell cycle, regulation of cell cycle, mitosis, nucleobase-containing compound
metabolic process, DNA replication, chromosome segregation, organelle organization, cell proliferation,
chromatin organization, and metabolic process. The downregulated genes also matched to four MF
terms (binding, catalytic activity, receptor activity and structural molecule activity). The PANTHER
Overrepresentation Test identified DNA helicase activity, helicase activity, kinase regulator activity,
nucleic acid binding and binding as overrepresented MFs. In the CC ontology, downregulated genes
matched six CC terms (cell part, organelle, macromolecular complex, membrane, extracellular matrix
and extracellular region). The PANTHER Overrepresentation Test identified the nucleus as the only
overrepresented CC.
Of the 171 annotated upregulated genes, 148 were recognized by the PANTHER database
and the highly enriched terms for three GO categories (BP, MF, CC) are presented in Figure 7A–C,
respectively. Overall, these genes matched to 12 BP 12 terms (cellular process, metabolic process,
localization, cellular component organization or biogenesis, response to stimulus, biological regulation,
developmental process, immune system process, multicellular organismal process, reproduction,
rhythmic process, cell killing), six MFs terms (catalytic activity, binding, transporter activity,
receptor activity, signal transducer activity, structural molecule activity) and six CC terms (cell
part, organelle, membrane, macromolecular complex, extracellular region, extracellular matrix).
The PANTHER Overrepresentation Test (FDR < 0.05) identified 10 significantly enriched BP terms
(steroid metabolic process, protein targeting, protein transport, vesicle-mediated transport, intracellular
protein transport, protein localization, transport, localization, single-multicellular organism process,
multicellular organismal process), one MF term (SNAP receptor activity), and six CC terms (vesicle
coat, SNARE complex, Golgi apparatus, cytoplasmic membrane-bounded vesicle, endoplasmic
reticulum, cytoplasm).




Figure 7Figure 7. PANTHER GO-Slim gene ontology hits for significant DEGs due to treatment with
0.1 µM monensin for 24 h (Monensin_only). (A) The down-regulated genes matched four MF
terms and the up-regulated genes matched six MF terms. The PANTHER Overrepresentation Test
(FDR < 0.05) identified five and one overrepresented MF terms for down- and up-regulated genes,
respectively. (B) The down-regulated genes matched 11 BPs and the up-regulated genes matched 12
BPs. The PANTHER Overrepresentation Test (FDR < 0.05) identified 11 and 10 overrepresented BPs for
down- and up-regulated genes, respectively. (C) The down-regulated genes matched six CCs while
up-regulated genes matched six CCs. The PANTHER Overrepresentation Test (FDR < 0.05) identified
one and six overrepresented CC terms for down- and up-regulated genes, respectively.
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All 236 annotated DEGs in the filtered list (log2 FC ≤ −1 or ≥ 1; adjusted p-value < 0.05)
were submitted to the Reactome Pathways Analysis tool (Available online: https://reactome.org/
PathwayBrowser/#TOOL=AT) together with their log2 FC values. Out of these, 132 were recognized
by the Reactome database and considered for pathway analysis. All 23 pathways linked with the
submitted genes with FDR < 0.05 are listed in Table 1. The table includes Reactome pathway identifiers,
pathway name, the number of matched genes, plus the pathway expression representation, which was
calculated from the average log2 FC of the matched genes. Overall, 17 pathways were upregulated,
whereas another six were downregulated. The most highly upregulated pathway was ‘PERK regulates
gene expression’ (R-HSA-381042) with an average log2 FC of 2.165, but the most downregulated
pathway was ‘G0 and early G1′ (R-HSA-1538133) with an average log2 FC of −1.179. Table 2 lists
pathways related to Wnt signalling, including their pathway’s identifiers, the number of matched
genes, FDR values and pathway expression representation by an average of log2 FC.
Table 1. All 23 Reactome pathways affected by 24 h of 0.1 µM monensin treatment (Monensin_only)
with FDR < 0.05.
Pathway ID Pathway Name Genes Found/Total Average Log2 FC
R-HSA-381119 Unfolded protein response (UPR) 31/160 1.440
R-HSA-381070 IRE1alpha activates chaperones 24/110 1.273
R-HSA-381038 XBP1(S) activates chaperone genes 21/106 1.293
R-HSA-1655829 Regulation of cholesterol biosynthesis by SREBP (SREBF) 19/86 1.279
R-HSA-2426168 Activation of gene expression by SREBF (SREBP) 16/70 1.295
R-HSA-199977 ER to Golgi anterograde transport 17/163 1.318
R-HSA-8957322 Metabolism of steroids 24/321 1.302
R-HSA-446203 Asparagine N-linked glycosylation 26/420 1.301
R-HSA-381183 ATF6 (ATF6-alpha) activates chaperone genes 6/15 1.766
R-HSA-381033 ATF6 (ATF6-alpha) activates chaperones 6/17 1.766
R-HSA-6807878 COPI-mediated anterograde transport 12/106 1.316
R-HSA-948021 Transport to the Golgi and subsequent modification 17/218 1.318
R-HSA-191273 Cholesterol biosynthesis 10/72 1.373
R-HSA-392499 Metabolism of proteins 75/2432 0.969
R-HSA-204005 COPII-mediated vesicle transport 9/76 1.381
R-HSA-6811442 Intra-Golgi and retrograde Golgi-to-ER traffic 14/217 1.127
R-HSA-176974 Unwinding of DNA 4/12 −1.121
R-HSA-381042 PERK regulates gene expression 6/38 2.165
R-HSA-1362300 Transcription of E2F targets under negative control byp107 (RBL1) and p130 (RBL2) in complex with HDAC1 4/20 −1.096
R-HSA-1538133 G0 and early G1 5/38 −1.179
R-HSA-1640170 Cell cycle 25/681 −0.763
R-HSA-6811438 Intra-Golgi traffic 5/48 1.558
R-HSA-5693554 Resolution of D-loop structures throughsynthesis-dependent strand annealing (SDSA) 4/30 −1.129
Note: Greyed rows indicate down-regulated pathways.
Table 2. Differentially expressed genes related to Wnt signaling (Monensin_only).





R-HSA-201681 TCF-dependent signalling in response to Wnt 2/216 1.232 0.918
Matched Genes HIST1H2AJ; HIST1H3F
R-HSA-195721 Signalling by Wnt 2/330 1.232 0.987
Matched Genes HIST1H2AJ; HIST1H3F
3.6.2. Control vs. TG_Monensin
Of 109 annotated downregulated genes, 101 were recognized by the PANTHER database and the
hits for all GO annotations (BP, MF, CC) and their major categories were presented in Figure 8A–C,
respectively. Overall, these downregulated genes matched 10 BP terms (biological adhesion, biological
regulation, cellular component organization or biogenesis, cellular process, developmental process,
localization, metabolic process, multicellular organismal process, reproduction, response to stimulus),
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three MF terms (binding, catalytic activity, structural molecule activity), and six CC terms (cell
part, extracellular matrix, extracellular region, macromolecular complex, membrane, organelle).
Further analysis with the PANTHER Overrepresentation Test (FDR < 0.05) revealed 25 significantly
enriched BP terms (Table 3), nine significantly enriched MF terms (DNA binding, nucleic acid binding,
DNA helicase activity, helicase activity, binding, single-stranded DNA binding, microtubule binding,
microtubule motor activity, motor activity), and 12 significantly enriched CC terms (chromosome,
nucleus, nuclear chromosome, organelle, protein-DNA complex, nucleoplasm, intracellular, cell part,
microtubule, plasma membrane, membrane, cytoskeleton).
Of 201 annotated up-regulated genes, 173 were recognized by the PANTHER database and the
hits for all GO annotations (BP, MF, CC) and their major categories are presented in Figure 8A–C,
respectively. Overall, these up-regulated genes matched to 11 BP terms (biological regulation, cellular
component organization or biogenesis, cellular process, developmental process, immune system
process, localization, locomotion, metabolic process, multicellular organismal process, reproduction,
response to stimulus), seven MF categories (antioxidant activity, binding, catalytic activity, receptor
activity, signal transducer activity, structural molecule activity, transporter activity), and six CC
terms (cell part, extracellular matrix, extracellular region, macromolecular complex, membrane,
organelle). Further analysis with the PANTHER Overrepresentation Test (FDR < 0.05) found nine
significantly enriched BPs (protein glycosylation, vesicle-mediated transport, protein transport,
protein localization, intracellular protein transport, transport, localization, single-multicellular
organism process, multicellular organismal process) and nine significantly enriched CC terms (vesicle
coat, SNARE complex, Golgi apparatus, cytoplasmic membrane-bounded vesicle, endoplasmic
reticulum, nuclear outer membrane-endoplasmic reticulum membrane network, cytoplasm, organelle,
intracellular), but no significantly enriched MF terms.
All 310 DEGs with a symbol from the filtered list (log2 FC ≤ −1 or ≥ 1; adjusted p-value < 0.05)
were submitted to the Reactome pathways analysis tool together with their log2 FC values. Out of these,
only 180 were recognized by the Reactome database and considered for pathway analysis. Pathways
linked with the submitted genes with FDR < 0.05 are listed in Table 4. Overall, the most up-regulated
pathway was ‘PERK regulates gene expression’ (R-HSA-381042) with an average log2 FC of 2.065,
whereas the most down-regulated pathway was ‘Resolution of D-loop structures through Holliday
junction intermediates’ (R-HSA-5693568) and ‘Resolution of D-Loop structures’ (R-HSA-5693537),
both with an average log2 FC of −1.239. Table 5 lists pathways related to Wnt signalling plus
their pathway’s identifiers, the number of matched genes, FDR values, and pathway expression
representation by an average of log2 FC.
Table 3. All 25 significantly enriched biological processes from 101 annotated upregulated genes, sorted
with the most significant at the top (TG_only).
PANTHER GO-Slim Biological Process (PO) No. of MatchedGenes FDR
DNA metabolic process (GO:0006259) 23 5.44 × 10−16
Nucleobase-containing compound metabolic process (GO:0006139) 38 1.04 × 10−7
Cell cycle (GO:0007049) 19 1.22 × 10−7
Chromosome segregation (GO:0007059) 9 1.51 × 10−7
Mitosis (GO:0007067) 11 1.1 × 10−6
DNA repair (GO:0006281) 9 6.88 × 10−6
Organelle organisation (GO:0006996) 21 1.04 × 10−5
Regulation of cell cycle (GO:0051726) 9 1.23 × 10−5
DNA replication (GO:0006260) 8 3.44 × 10−5
Nitrogen compound metabolic process (GO:0006807) 30 4.27 × 10−5
Chromatin organisation (GO:0006325) 9 1.87 × 10−4
Metabolic process (GO:0008152) 48 6.35 × 10−4
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Table 3. Cont.
PANTHER GO-Slim Biological Process (PO) No. of MatchedGenes FDR
Primary metabolic process (GO:0044238) 41 1.18 × 10−3
DNA recombination (GO:0006310) 4 2.59 × 10−3
Cellular component organisation (GO:0016043) 22 3.08 × 10−3
Cell communication (GO:0007154) 2 3.69 × 10−3
Cellular component organisation or biogenesis (GO:0071840) 22 5.55 × 10−3
Regulation of gene expression, epigenetic (GO:0040029) 4 6.23 × 10−3
Chromatin assembly (GO:0031497) 3 0.0146
Signal transduction (GO:0007165) 2 0.0147
Meiosis (GO:0007126) 3 0.0433
Multicellular organismal process (GO:0032501) 1 0.0459
Single-multicellular organism process (GO:0044707) 1 0.0469
Cell surface receptor signalling pathway (GO:0007166) 0 0.0485
Cell proliferation (GO:0008283) 3 0.0487
Table 4. The top 30 out of 55 Reactome pathways affected by T. gondii infection and treatment with
0.1 µM monensin (TG_Monensin). Among the 310 genes submitted, only 180 were recognized by the
Reactome database and considered for analysis.
Pathway ID Pathway Name No. of MatchedGenes
Average
Log2 FC
R-HSA-381038 XBP1(S) activates chaperone genes 27/106 1.399
R-HSA-381070 IRE1alpha activates chaperones 30/110 1.373
R-HSA-381119 Unfolded protein response (UPR) 38/160 1.469
R-HSA-69278 Cell cycle, mitotic 43/569 −1.000
R-HSA-1640170 Cell cycle 47/681 −1.017
R-HSA-1538133 G0 and early G1 10/38 −1.091
R-HSA-446203 Asparagine N-linked glycosylation 31/420 1.307
R-HSA-199977 ER to Golgi anterograde transport 18/163 1.343
R-HSA-453279 Mitotic G1-G1/S phases 17/173 −1.091
R-HSA-69620 Cell cycle Checkpoints 22/279 −1.017
R-HSA-381183 ATF6 (ATF6-alpha) activates chaperone genes 6/15 1.612
R-HSA-6811442 Intra-Golgi and retrograde Golgi-to-ER traffic 19/217 0.809
R-HSA-6807878 COPI-mediated anterograde transport 13/106 1.362
R-HSA-381033 ATF6 (ATF6-alpha) activates chaperones 6/17 1.612
R-HSA-392499 Metabolism of proteins 92/2432 0.796
R-HSA-948021 Transport to the Golgi and subsequent modification 18/218 1.343
R-HSA-1362300 Transcription of E2F targets under negative control by p107(RBL1) and p130 (RBL2) in complex with HDAC1 6/20 −1.054
R-HSA-6811434 COPI-dependent Golgi-to-ER retrograde traffic 12/106 0.447
R-HSA-141424 Amplification of signal from the kinetochores 11/94 −0.858
R-HSA-141444 Amplification of signal from unattached kinetochores via a MAD2inhibitory signal 11/94 −0.858
R-HSA-69618 Mitotic spindle checkpoint 11/110 −0.858
R-HSA-68886 M Phase 23/389 −0.912
R-HSA-2500257 Resolution of sister chromatid cohesion 12/133 −0.872
R-HSA-5693568 Resolution of D-loop structures through Holliday junctionintermediates 6/36 −1.239
R-HSA-8856688 Golgi-to-ER retrograde transport 12/147 0.447
R-HSA-5693537 Resolution of D-Loop structures 6/37 −1.239
R-HSA-381042 PERK regulates gene expression 6/38 2.065
R-HSA-69206 G1/S Transition 12/150 −1.103
R-HSA-1362277 Transcription of E2F targets under negative control by DREAMcomplex 5/25 −1.070
R-HSA-774815 Nucleosome assembly 7/54 −1.108





Figure 8. PANTHER GO-Slim gene ontology hits for significant DEGs due to T. gondii infection and
treatment with monensin (TG_Monensin). (A) The down-regulated genes matched 3 MFs while
the up-regulated genes matched seven MFs. The PANTHER Overrepresentation Test (FDR < 0.05)
identified nine MFs down-regulated genes but none for up-regulated genes. (B) The down-regulated
genes matched 10 BP terms while the up-regulated genes matched 11 terms. The PANTHER
Overrepresentation Test (FDR < 0.05) identified 25 and nine overrepresented BPs for down- and
up-regulated genes, respectively. (C) The down-regulated genes matched six CC terms while the
up-regulated genes matched six CC terms. The PANTHER Overrepresentation Test (FDR < 0.05)
identified 12 and nine overrepresented CCs for down-regulated and up-regulated genes, respectively.
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Table 5. Expressed genes related to Wnt signaling (TG_Monensin) according to the Reactome
classification.





R-HSA-195721 Signalling by Wnt 5/330 −1.207 0.911
Matched Genes HIST1H2BM; HIST1H2AJ; HIST1H3F; HIST1H3G; HIST1H2BE; HIST1H3B; HIST1H2AB
R-HSA-201681 TCF-dependent signalling in response to Wnt 5/216 −1.207 0.617
Matched Genes HIST1H2BM; HIST1H2AJ; HIST1H3F; HIST1H3G; HIST1H2BE; HIST1H3B; HIST1H2AB
Note: HIST1H2BM/HIST1H2BE and HIST1H3B/HIST1H3F are duplicated genes.
3.6.3. Control vs. TG_only
Of 103 annotated down-regulated genes, only 38 were recognized by the PANTHER database,
and the hits for all GO annotations (BP MF, CC) and their major categories were presented in
Figure 9A–C. Overall, these upregulated genes matched to 9 BP terms (cellular process, metabolic
process, localization, biological regulation, response to stimulus, cellular component organization or
biogenesis, multicellular organismal process, developmental process, biological adhesion), five MF
terms (binding, catalytic activity, transporter activity, signal transducer activity, receptor activity)
and seven CC terms (cell part, organelle, macromolecular complex, membrane, extracellular region,
synapse, extracellular matrix). Further analysis with the PANTHER Overrepresentation Test found no
significantly enriched BP, MF or CC (FDR < 0.05).
Of 345 annotated up-regulated genes, only 280 were recognized by the PANTHER database
and the hits for all GO annotations (BP MF, CC) and their major categories were presented in
Figure 9A–C, respectively. Overall, these up-regulated genes matched to 14 BP terms (biological
adhesion, biological regulation, cellular component organization or biogenesis, cellular process,
developmental process, growth, immune system process, localization, locomotion, metabolic process,
multicellular organismal process, reproduction, response to stimulus, rhythmic process), eight MF
terms (antioxidant activity, binding, catalytic activity, channel regulator activity, receptor activity, signal
transducer activity, structural molecule activity, transporter activity) and eight CC terms (cell junction,
cell part, extracellular matrix, extracellular region, macromolecular complex, membrane, organelle,
synapse). Further analysis with the PANTHER Overrepresentation Test found BP to be significantly
enriched, but there were no significantly enriched MF or CC (FDR < 0.05).
All 448 DEGs with a symbol from the filtered list (log2 FC ≤ −1 or ≥ 1; adjusted p value < 0.05)
were submitted to Reactome’s ‘Pathways Analysis’ tool together with their log2 FC values. Out of these,
only 232 were recognized by the Reactome database and considered for pathway analysis. Pathways
linked to the submitted genes with FDR < 0.05 are listed in Table 6. Surprisingly, even though there
were more genes submitted compared to Monensin_only, only four pathways passed the corrected
overrepresentation probability test (FDR < 0.05). All four pathways were upregulated, with the most
highly upregulated pathway being ‘Interferon alpha/beta signalling’ (R-HSA-909733) with an average
log2 FC of 1.57. Table 7 lists pathways related to the Wnt signalling plus their pathway’s identifiers,
the number of matched genes, FDR values, and pathway expression representation by an average of
log2 FC.
Table 6. Reactome pathways affected by T. gondii infection (TG_only) with FDR < 0.05.
Pathway ID Pathway Name Genes Found/Total Average Log2 FC
R-HSA-909733 Interferon alpha/beta signalling 38/184 1.611
R-HSA-913531 Interferon Signalling 50/388 1.532
R-HSA-1280215 Cytokine Signalling in the Immune system 72/1051 1.535
R-HSA-877300 Interferon gamma signalling 23/250 1.359
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Test (FDR < 0.05) for both sets of genes. (B) The down-regulated genes matched nine PBs while the
up-regulated genes matched 14 BPs. The PANTHER Overrepresentation Test (FDR < 0.05) identified
two overrepresented BPs from up- but none for down-regulated genes. (C) The down-regulated genes
matched seven CC terms while the up-regulated genes matched eight CC terms. No overrepresented
CC was identified from the PANTHER Overrepresentation Test (FDR < 0.05) for both sets of genes.
Table 7. Differentially expressed genes involved in Wnt signaling (TG_only) according to the
Reactome classification.





R-HSA-195721 Signalling by Wnt 7/330 1.303 0.937
Matched Genes HIST1H4B; FZD7; HIST1H2BG; HIST2H3D; PLCB1; GNG11; HIST1H2AB
R-HSA-201681 TCF-dependent signalling in response to Wnt 4/216 1.279 0.939
Matched Genes HIST1H4B; HIST1H2BG; HIST2H3D; HIST1H2AB
R-HSA-3858494 Beta-catenin independent Wnt signalling 3/165 1.335 0.923
Matched Genes FZD7; PLCB1; GNG11
4. Discussion
In this study, we utilized microarray analysis to evaluate the transcriptome profile of
T. gondii-infected hBMECs treated with the Wnt inhibitor monensin. First, we investigated the
effect of Wnt inhibition by monensin on the in vitro growth of T. gondii inside hBMECs and microglia
cells. T. gondii growth inhibition was evidenced by the significant reduction in the number of tachyzoites
(Figure 1) and the relative similarity in cell density levels (Figure 2) between infected and non-infected
cultures. Our data showed that parasite inhibition increased as the concentration of monensin increased
(i.e. dose-dependent) and that monensin at 0.1 µM concentration significantly decreased the growth
of T. gondii tachyzoites. Consistent with this, it has been reported that monensin reduced T. gondii
growth in human foreskin fibroblasts [26,27]. Our result also fits within the effective range of monensin
concentrations (0.01 and 0.1 µM) reported against human cytomegalovirus (HCMV) [14]. Interestingly,
monensin was more effective in inhibiting T. gondii growth in hBMECs compared to microglia cells.
Moreover, in the presence of monensin treatment, infected and noninfected hBMECs exhibited
significant reduction in their growth rates. However, the differential variation in the magnitude of
cell growth reduction between the two cell lines suggests that monensin had more cytotoxic effect on
hBMECs compared to microglia cells. These findings were the basis for choosing hBMECs to determine
the effects of monensin on host gene transcription in the context of T. gondii infection.
Next, we determined the effect of T. gondii with or without monensin treatment on the integrity
of cerebrovascular endothelial cell monolayer. Our findings showed that T. gondii infection can
compromise the integrity of BBB endothelial cells compared to uninfected cells (p < 0.05; Figure 3).
Consistent with our finding, T. gondii was reported to compromise the cell integrity to facilitate
a paracellular migration route across the BBB [28]. Cellular barrier function is mediated through
intercellular tight junction (TJ) proteins, which can be dysregulated by T. gondii infection to increase
barrier permeability and parasite crossing [29]. Alteration in the TJ function may occur either through
a direct effect of T. gondii infection on the host cell cytoskeleton [30] or via the indirect action of
T. gondii-induced proinflammatory cytokines, which can promote the opening of TJ that would in turn
allow leukocytes to migrate across the endothelial barrier into cerebral tissue [31,32]. T. gondii-infected
and treated hBMECs seemed to maintain their resistance, presumably due to the inhibitory effect of
monensin on T. gondii growth, thereby protecting cells from cytoskeletal rearrangement associated
with parasite invasion and growth, which compromises TJ and BBB integrity. Given the ability of this
parasite to invade and use leukocytes as a Trojan-horse to migrate across the BBB [33], further studies
should investigate how monensin may influence the effect of T. gondii on leukocytes’ ability to cross
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the BBB. If monensin is effective in inhibiting T. gondii growth inside leukocytes, then this may thwart
the parasite’s ability to disseminate to the CNS tissue.
The exact mechanism of anti-T. gondii activity of monensin is unknown, however this compound
seems to exert its action by directly interfering with one or more functions in the parasite. For example,
osmotic swelling of the parasite [34], presumably due to its inability to regulate ionic homeostasis
as a result of Na+ influx [35], interference with vesicular trafficking [36], altering the parasite’s cell
cycle [26], or inducing nutrient stress and TgMSH-1-mediated autophagy [27], have all been suggested
to contribute to T. gondii death. Interestingly, pre-treatment of hBMECs with monensin inhibited the
susceptibility of hBMEC to gram-negative bacteria Citrobacter freundii [37] and Brucella abortus [38]
invasion or survival in a dose-dependent manner. Monensin exhibits potent anticancer activity on
several types of cancer, by inhibiting cell proliferation, cell cycle progression, and cell migration and by
inducing apoptosis [39]. Monensin may also accomplish its anticancer effect by targeting multiple
signaling pathways, particularly the epidermal growth factor receptor (EGFR) and Wnt signaling
pathways [39,40]. Given these pervasive effects of monensin, it is possible that monensin exerts its
anti-T. gondii effect, by altering the host response to infection in addition to its direct antiparasitic effect.
Therefore, we investigated whether the secondary effects of monensin on the host cells may
contribute to parasite clearance. We performed microarray analysis to test the hypothesis that treatment
with 0.1 µM monensin modulates signalling pathways, such as the Wnt pathway, which in turn inhibits
T. gondii infection and enhances hBMECs survival. The microarray quality control checks indicated
that the datasets had acceptable quality. Variations within samples were minimal (Figure 4) and
variations between samples were made comparable by RMA normalization (Figure S1). Our analysis
revealed 480 DEGs in hBMECs treated with monensin compared to control untreated hBMECs. Since
monensin induced significant changes in the gene transcription of treated cells, we wanted to investigate
whether monensin also can cause the same changes in the presence of T. gondii infection. Interestingly,
424 DEGs were detected in T. gondii-infected hBMECs treated with monensin compared to control
hBMECs. When we compared DEGs in monensin-treated uninfected cells to DEGs in monensin-treated
T. gondii-infected cells, different levels of expression of specific genes were detected between the
two groups, showing the differential response of treated cells in the presence or absence of infection.
This finding is anticipated because a subset of these DEGs can be expected to be mechanistically
involved in the infection process and thus their expression is unlikely to change in response to treatment
per se. Interestingly, the TG_only group expression profile was distinct from the expression profiles
of the other three groups (TG_Monensin group, Monensin_only group and Control_only group) as
shown in the dendrogram (Figure 4A). This clustering is supported by the detection of 902 DEGs in
hBMECs infected by T. gondii without monensin treatment (TG_only group), compared to 424 DEGs
detected in infected and treated cells (TG_Monensin group). Such a significantly large number of
DEGs in the TG_only group indicates that monensin must have attenuated the adverse impact of
T. gondii infection on the treated cells, probably by interfering with signalling pathways essential for
the parasite growth or via direct inhibition of the parasite proliferation, providing further support to
the antiparasitic effect of monensin observed in Figures 1 and 2.
PANTHER GO enrichment analysis, used to functionally annotate all DEGs in each group,
revealed similar terms in the three GO categories between the examined groups. Reactome pathway
enrichment analysis of the DEGs of hBMECs treated with monensin revealed that monensin treatment
downregulated pathways related to steroids, cholesterol and protein biosynthesis and their transport
between endoplasmic reticulum (ER) and Golgi apparatus. Transcriptional analysis of T. gondii-infected
hBMECs treated with monensin revealed a similar transcriptional pattern to the Monensin_only group.
These results suggest that parasite inhibition may have been achieved through dysregulation of the
biosynthesis of key nutrients in the host cells and/or inhibition of nutrient transport between cell
organelles, limiting their transport into parasitophorous vacuole. This finding is consistent with a
previous transcriptomic study of monensin-treated porcine kidney (PK)-15 cells, which revealed an
overrepresentation of the downregulated genes involved in the biosynthesis of spliceosome, ribosome,
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and protein processing in ER, suggesting that monensin, via down-regulation of protein biosynthesis,
can limit the parasite growth and proliferation [41].
Our data also showed that monensin administration modulated pathways related to DNA
replication in the nucleus and cell cycle. In our study, we have identified 39 significantly upregulated
pathways related to DNA replication, cell cycle and cell division in the TG_Monensin group compared
to only three significantly upregulated pathways from the Monensin_only transcriptome data.
The significantly increased number of these upregulated pathways in the TG_Monensin group is
probably attributed to the dual effects of monensin and parasite infection on the host cell transcriptome.
The effects of monensin on DNA synthesis, and repair of the parasite and the host cells, can be also
inferred from the downregulated pathways identified in both the Monensin_only and the TG_Monensin
groups. Some of the downregulated pathways were related to DNA repair mechanisms, such as
resolution of D-loop structures through Holliday junction intermediates (R-HSA-5693568), resolution
of D-loop structures (R-HSA-5693537), resolution of D-loop structures through synthesis-dependent
strand annealing (R-HSA-5693554), and unwinding of DNA (R-HSA-176974). In addition, key DNA
repair mechanisms related to molecular functions, such as DNA helicase activity (GO:0003678), helicase
activity (GO:0004386), kinase regulator activity (GO:0019207), nucleic acid binding (GO:0003676) and
binding (GO:0005488), were also identified as overrepresented (PANTHER Overrepresentation Test)
from downregulated genes of the Monensin_only group.
Interestingly, both the Monensin_only and the TG_Monensin groups downregulated cell
cycle-related pathways (e.g. cell cycle (R-HSA-1640170); G0 and early G1 (R-HSA-1538133) and
transcription of E2F targets under negative control by p107/RBL1 and p130/RBL2 in complex
with HDAC1 [R-HSA-1362300]) and upregulated PERK regulates gene expression (R-HSA-381042),
which leads to cell cycle arrest in host cells. Monensin has been shown to arrest the parasite cell cycle
process [26]. Thus, we can infer that monensin can inhibit both parasite and host cell cycle processes that
ultimately lead to growth inhibition of T. gondii. This finding is consistent with the upregulation of the
DNA damage-inducible transcript 3 (DDIT3), a key gene in the upregulated pathway, which encodes a
stress-inducible transcription factor that induces cell cycle arrest and apoptosis in mammalian cells.
Our finding is consistent with a previous study that showed that monensin induced DDIT3, a key
inhibitor of the Wnt signalling pathway [42], in prostate cancer cells [43]. The key genes identified in
those downregulated pathways are CCNA2, that controls both the G1/S and the G2/M transition phases
of the cell cycle, and MYBL2, that functions as a physiological regulator of cell cycle progression. While
there are no published data that show the inhibitory effect of monensin on CCNA2, there are reports on
monensin as a potent inhibitor of the MYB gene family that includes MYBL1 and MYBL2 [44–46].
The link between T. gondii and the Wnt signalling pathway has been already established. In one
study, the Wnt pathway was found to be upregulated during T. gondii infection in brain cells [47].
In another study, the virulence factor ROP18 of T. gondii was found to inhibit the Wnt signalling
pathway in neural stem cells [48]. In the present study, Wnt signalling and Wnt-related pathways were
not significantly affected by treatment with 0.1 µM monensin, rejecting the hypothesis that inhibition
of T. gondii growth is largely mediated by the aberrant Wnt signalling in the host cells due to monensin
treatment. All Wnt-related genes, such as Frizzled receptors, beta-catenin and protein kinase C (PKC)
had modest expression after treatment. The same also applies to the transcriptome of TG_only and
TG_Monensin groups. This finding suggests that monensin treatment did not affect the Wnt signalling
pathway in hBMECs and that inhibition of T. gondii infection in hBMECs following monensin treatment
was not achieved through direct blocking of the Wnt signalling pathway. Our study did however
identify changes in the expression of genes related to other signal pathways involved in cell cycle
control, apoptosis, and DNA synthesis and repair. These data further support the pleiotropic effects of
monensin on multiple biological processes.
We were also interested in comparing host gene expression in uninfected to T. gondii-infected
hBMECs in the absence of monensin treatment to better understand the types of host responses induced
by infection. The transcriptome analysis of hBMECs infected with T. gondii for 24 h (TG_only) revealed
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significantly increased interferon-alpha/beta and gamma signalling-related pathways. This finding
is consistent with previous transcriptome studies in murine macrophages [49] and human fibroblast
cells [50], reaffirming the deregulation of the immune response following T. gondii infection of
hBMECs. The increased expression of the MT1M gene was also reported previously [51], where MT1M
upregulation has been suggested to contribute to the cellular homeostasis of transition metals,
particularly zinc, during T. gondii infection. The down-regulation of microRNA 29a has also been
reported in a mouse brain infected by the cystogenic strain (type II) [52], which is less virulent than
the RH (type I) strain used in our study, suggesting that inhibition of microRNA 29a is common in
T. gondii infection, independent of the parasite virulence.
5. Conclusions
We showed that the ionophore monensin, an inhibitor of the Wnt pathway, had a significant
anti-T. gondii activity against the tachyzoite stage of T. gondii grown in hBMECs and microglia in vitro at
0.1 µM concentration. We also showed an association between T. gondii infection and compromisation
of the hBMEC integrity, which was restored by treatment with 0.1 µM monensin. Transcriptome
analysis provided evidence that treatment of hBMECs with monensin is accompanied by reduced
expression of genes in pathways involved in steroids, cholesterol and protein biosynthesis and their
transport between ER and Golgi apparatus. These data indicate that inhibition of T. gondii infection in
hBMECs was not directly achieved through blocking Wnt signalling and that anti-T. gondii activity of
monensin appears to be mediated independently of the Wnt pathway. Rather, our findings support the
notion that parasite inhibition was in part due to inhibition of transport between organelles within cells
and limiting nutrient transport into parasitophorous vacuole. In addition, monensin seems to inhibit
the parasite growth through interference with cell cycle and DNA synthesis and repair mechanisms.
More studies to elucidate how host-targeted effects of monensin on hBMECs inhibits T. gondii infection
are warranted. Future work should also include experiments on the protein level to assess whether
differential gene regulation is paralleled by similar proteomic changes.
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Normalization improved the overall distribution between samples and rendered the data more balanced for
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